Onzima Ventures
PLC
("Onzima" or the "Company")
N4 Pharma
announces further patent filings for reformulation of Valsartan and
Losartan
Onzima is pleased to announce that N4 Pharma Limited ("N4
Pharma"), its 49%-owned investee company, has filed 17 novel
patents for the reformulation of losartan and 12 novel patents for
the reformulation of valsartan.
This is in line with its strategy of filing strong broad patents
for a range of drugs that it wishes to consider reformulating and
are part of the suite of patents that N4 Pharma acquired from
OPAL IP.
N4 Pharma CEO Nigel Theobald
commented: "These are the first of a range of other
reformulation patents we intend to file for a number of existing
generic or soon to be generic drugs in addition to those already
filed for Sildenafil.
“We will continue to file strong life cycle management patents
for a range of drugs over the coming weeks and months. Our initial
formulation focus is still on our work for Sildenafil and we are
now working with clinicians and formulators to decide which of
these additional new drugs we will start reformulation work on
next.
“Sartans are the most recent class of anti-hypertensive agents
and are extremely effective at relaxing smooth muscle in the
arteries and thereby relieve hypertension. Since sartans are
effectively metabolised by the body, the drug level is not
effectively maintained in the body overnight which causes increased
blood pressure on waking, resulting in potential patient health
issues.
“Our reformulation will look to maintain the dose more
effectively overnight thereby reducing the nocturnal deficit of the
drug and maintain low blood pressure throughout the drug dose,
giving a unique clinical position in the sartans market which, in
2015, returned global sales of $11bn".
For further information please
contact:
Onzima Ventures
PLC
Tel: +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers
LLP
Tel: +44 (0)
20 7148 7900
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance Limited
Tel: +44 (0) 20 7469 0930
Guy Miller, Lucy Williams